Identifying miltefosine-resistant key genes in protein–protein interactions network and experimental verification in Iranian Leishmania major

Lari, Niloofar; Jalal, Razieh; Minuchehr, Zarrin; Rajabian, Majid

doi:10.1007/s11033-019-04992-4

Cited by 5 publications

(1 citation statement)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, Leishmania major miltefosine transporter (LmMT) markers and small hydrophilic endoplasmic reticulum-associated protein (SHERP) genes were also detected in Iranian MIL-resistant L. major parasites. Therefore, these data recommended PP2C, SHERP and LmMT as the potential drug objects for MIL-resistant Leishmania major therapy [ 45 ].…”

Section: General Proteomic Approach In Different Type Of Leishmaniasismentioning

confidence: 99%

Omics Approaches in Drug Development against Leishmaniasis: Current Scenario and Future Prospects

Rabaan

Bakhrebah

Mohapatra³

et al. 2022

Pathogens

View full text Add to dashboard Cite

Leishmaniasis is a zoonotic disease transmitted in humans by the bite of Leishmania-infected phlebotomine sandflies. Each year approximately 58,500 cases of leishmaniasis are diagnosed across the globe, with a mortality rate of nearly seven percent. There are over 20 parasitic strains of Leishmania which are known to cause distinct types of leishmaniasis and pose an endemic threat to humans worldwide. Therefore, it is crucial to develop potential medications and vaccines to combat leishmaniasis. However, the task of developing therapeutic solutions is challenging due to Leishmania's digenetic lifecycle. The challenge is further intensified by cases of resistance against the available drugs. Owing to these challenges, the conventional drug development regimen is further limited by target discovery and ligand suitability for the targets. On the other hand, as an added advantage, the emergence of omics-based tools, such as high-end proteomics, transcriptomics and genomics, has hastened the pace of target discovery and target-based drug development. It is now becoming apparent that multi-omics convergence and an inter-connected systems approach is less time-consuming and more cost-effective for any drug-development process. This comprehensive review is an attempt to summarize the current knowledge on the muti-omics approach in drug development against leishmaniasis. In particular, it elaborates the potential target identification from secreted proteins in various stages of Leishmania infection and also illustrates the convergence of transcriptomic and genomic data towards the collective goal of drug discovery. This review also provides an understanding of the potential parasite’s drug targets and drug resistance characteristics of the parasite, which can be used in designing effective and specific therapeutics.

show abstract

Section: General Proteomic Approach In Different Type Of Leishmaniasismentioning

confidence: 99%

Omics Approaches in Drug Development against Leishmaniasis: Current Scenario and Future Prospects

Rabaan

Bakhrebah

Mohapatra³

et al. 2022

Pathogens

View full text Add to dashboard Cite

show abstract

Parasite protein phosphatases: biological function, virulence, and host immune evasion

et al. 2021

View full text Add to dashboard Cite

DNA-based microarray studies in visceral leishmaniasis: identification of biomarkers for diagnostic, prognostic and drug target for treatment

2020

View full text Add to dashboard Cite

Identifying miltefosine-resistant key genes in protein–protein interactions network and experimental verification in Iranian Leishmania major

Cited by 5 publications

References 67 publications

Omics Approaches in Drug Development against Leishmaniasis: Current Scenario and Future Prospects

Omics Approaches in Drug Development against Leishmaniasis: Current Scenario and Future Prospects

Parasite protein phosphatases: biological function, virulence, and host immune evasion

DNA-based microarray studies in visceral leishmaniasis: identification of biomarkers for diagnostic, prognostic and drug target for treatment

Contact Info

Product

Resources

About